Entera Bio Ltd. ENTX 深 滬
已收盤 02-06 16:00:00 美东时间
1.04
-0.130
-11.11%
華盛通- 最 高1.215
- 今 開1.14
- 成交量 35.61万股
- 最 低 1.00
- 昨 收 1.17
- 總市值 4769.15万
- 52周最高 3.22
- 市盈率 靜 --
- 換手率 0.78%
- 52周最低 1.00
- 委 比 -43.37%
- 總股本 4585.72万
- 歷史最高 10.16
- 量 比 1.59
- 振 幅 18.38%
- 歷史最低 0.472
- 每 手 1
- 風險率 0.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多OPKO Health Expands Partnership With Entera Bio To Advance First-in-Class Oral Long Acting PTH Tablet
This is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilitiesThe companies have accelerated this program and aim to file an
02-04 21:05
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
Entera Bio Ltd. announced its key milestones for Q1 2026, including submitting the final Phase 3 protocol for EB613 to the FDA, expecting results from the Next-Generation EB613 Phase 1 bridging study, accelerating its hypoparathyroidism program with long-acting PTH variants, and advancing strategic partnerships across its pipeline. The Company remains committed to addressing unmet medical needs in osteoporosis and hypoparathyroidism.
01-21 13:30
Entera Bio Announces New Validating In Vivo Pharmacokinetic And Pharmacodynamic Data That Supports Development Of Proprietary Long-Acting PTH Analog Using N-Tab Platform For Patients With Hypoparathyroidism
Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides and proteins replacement therapies, today announced new validating in vivo pharmacokinetic and pharmacodynamic data
2025-12-22 21:33
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
Entera Bio announced preclinical success in developing a novel, long-acting PTH analog using its N-Tab® platform. The analog achieved sustained calcium elevation for over three days with a single oral dose, addressing the need for a once-daily tablet alternative to daily injections for hypoparathyroidism patients. The study showed significantly longer plasma half-life and no adverse events, marking a potential breakthrough in treatment convenienc...
2025-12-22 13:30
Entera Bio GAAP EPS of $0.07
Entera Bio press release (ENTX): Q3 GAAP EPS of $0.07. Research and development expenses were $1.6 million for the three months ended September 30, 2025, compared to $1.5 million for the same period i...
2025-11-15 05:50
Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates
2025年第三季度，Entera Bio宣布其骨质疏松治疗药物EB613获得FDA同意，将BMD作为注册性III期研究的主要终点。EB613的II期数据显示，该药物可显著提升 trabecular 和 cortical 骨指标，且在年轻绝经后女性中展现出一致疗效。此外，EB613下一代产品预计于2025年底启动I期试验。公司还展示了GLP-2在短 bowel综合征和OXM在肥胖症中的积极前临床数据。财务方面，截至9月底，公司现金及现金等价物为1660万美元，净亏损320万美元。
2025-11-14 21:05
Entera Bio Releases New Phase 2 Data At NAMS 2025 Showing That EB613, An Oral PTH[1-34] Therapy, Consistently Increased Bone Mineral Density In Both Early Postmenopausal Women And Those 10 Years Post-Menopause
Consistency of BMD gains presented at NAMS 2025 demonstrate EB613's efficacy in both young postmenopausal women and in women 10 years post-menopauseData further support EB613 potential as a first-in-class oral anabolic
2025-10-23 20:58
Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women
<p>Entera Bio的EB613在NAMS 2025会议上展示了其在早期和更晚更年期女性中的BMD提升效果，表明其作为首个口服骨形成疗法的潜力，可显著扩大患者对骨疗法的可及性。Entera计划在2025年7月FDA同意后启动全球注册性III期研究。EB613在II期试验中显示，2.5 mg剂量在早期更年期女性脊柱、股骨颈和髋部BMD有显著提升，效果与晚期更年期女性相当。该产品有望改变骨质疏松治疗方式，提高患者依从性，并有望成为首个口服骨形成治疗选项。</p>
2025-10-23 12:50
Entera Bio Announces It Will Present New Phase 2 Clinical Data For EB613 At The North American Menopause Society 2025 Annual Meeting, October 21–25, 2025, In Orlando, Florida.
Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced that it will present new clinical data from its Phase 2 trial of EB613 at the upcoming North
2025-10-16 20:47
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
Entera Bio will present Phase 2 data for EB613 at the NAMS 2025 Annual Meeting, focusing on bone mineral density outcomes in early postmenopausal women with low bone mass or osteoporosis. EB613, the first oral anabolic tablet, aims to address the underutilization of injectable anabolic therapies by providing a once-daily treatment option. The study met all biomarker and BMD endpoints, demonstrating increases in lumbar spine, total hip, and femora...
2025-10-16 12:45
